CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.96B, above the global median of $1.15B
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.96BUSDvs all stocks (USD)
Revenue (TTM)
140.49MUSDvs all stocks (USD)
Profit Margin
-94.83%vs Biotechnology peers
Beta
1.57xvs all stocks
52-Week Change
160.22%vs all stocks
Market Capitalization
1.96BUSDvs all stocks (USD)
Enterprise Value
2.02BUSDvs all stocks (USD)
Forward P/E
29.18xvs Biotechnology peers
Price to Sales (TTM)
13.95xvs Biotechnology peers
Enterprise to Revenue
14.36xvs Biotechnology peers
Enterprise to EBITDA
-18.69xvs Biotechnology peers
Gross Margin
91.88%vs Biotechnology peers
Profit Margin
-94.83%vs Biotechnology peers
Operating Margin
-39.76%vs Biotechnology peers
Return on Assets (TTM)
-26.98%vs Biotechnology peers
Revenue (TTM)
140.49MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.88USDUpdated Jul 19, 2026Quarterly Revenue Growth
151.60%vs Biotechnology peers
Gross Profit (TTM)
126.24MUSDvs all stocks (USD)
EBITDA (TTM)
-107.90MUSDvs all stocks (USD)
Net Income (TTM)
-133.22MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
151.60%vs Biotechnology peers
Operating Cash Flow (TTM)
-165.74MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-109.28MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
109.79MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
12.45MUSDFY2025 · Dec 31, 2025Gross Profit
97.34MUSDFY2025 · Dec 31, 2025Operating Income
-124.86MUSDvs all stocks (USD)
Pre-tax Income
-153.42MUSDFY2025 · Dec 31, 2025Income Tax Expense
78.00KUSDFY2025 · Dec 31, 2025Net Income
-153.49MUSDFY2025 · Dec 31, 2025EBIT
-138.07MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-135.66MUSDFY2025 · Dec 31, 2025Research & Development
67.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
155.10MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
15.35MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.19USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.19USDFY2025 · Dec 31, 2025Basic Shares Outstanding
48.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
48.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-153.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-160.55MUSDFY2025 · Dec 31, 2025Free Cash Flow
-160.84MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.41M of depreciation against 289K of capital expenditure, and its own free-cash-flow line reads -162.73M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
112.09MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-153.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.41MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.60MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.78MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
286.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.54MUSDFY2025 · Dec 31, 2025Capital Expenditures
-289.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-77.40MUSDFY2025 · Dec 31, 2025Sale of Investments
139.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
61.56MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.85MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
37.95MUSDFY2025 · Dec 31, 2025Shares Outstanding
48.71MSharesUpdated Jul 19, 2026Float Shares
43.20MSharesUpdated Jul 19, 2026Shares Short
6.22MSharesUpdated Jul 19, 2026Short Ratio
9.27daysvs all stocks
Short % of Shares Outstanding
13.02%vs all stocks
% Held by Insiders
3.62%vs all stocks
% Held by Institutions
101.02%vs all stocks
Total Cash (MRQ)
140.27MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.88USDUpdated Jul 19, 2026Total Debt (MRQ)
197.09MUSDvs all stocks (USD)
Current Ratio (MRQ)
4.69xvs Biotechnology peers
Book Value per Share (MRQ)
-2.55USDUpdated Jul 19, 2026Total Assets
200.46MUSDvs all stocks (USD)
Total Current Assets
186.02MUSDFY2025 · Dec 31, 2025Total Liabilities
305.93MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.43MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
259.51MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
110.75MUSDFY2025 · Dec 31, 2025Other Short-term Investments
9.71MUSDFY2025 · Dec 31, 2025Accounts Receivable
33.08MUSDFY2025 · Dec 31, 2025Inventory
16.46MUSDFY2025 · Dec 31, 2025Accounts Payable
12.14MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.18MUSDFY2025 · Dec 31, 2025Long-term Debt
128.33MUSDFY2025 · Dec 31, 2025Common Stock (Book)
133.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-959.72MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-105.47MUSDvs all stocks (USD)
52-Week Low
15.04USDUpdated Jul 19, 202652-Week High
41.88USDUpdated Jul 19, 202652-Week Change
160.22%vs all stocks
Beta
1.57xvs all stocks
50-Day MA
32.29USDUpdated Jul 19, 2026200-Day MA
23.89USDUpdated Jul 19, 2026Avg 10-Day Volume
892.23KSharesUpdated Jul 19, 2026Avg 30-Day Volume
754.74KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.74USDUpdated Jul 19, 2026Other Income / Expense
-670.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.92Profit Margin: -0.95
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.96B, above the global median of $1.15BNotable
Market cap (USD): 1,960,074,031Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Ocular Therapeutix Inc.
Tier 1ProductionApproval-Gated PipelineRule
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Aosaikang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCRevenue Growing With Receivables Growing
Iovance Biotherapeutics, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCRevenue Growing With Receivables Growing
Butler National Corporation
1 interpretationRevenue Growing With Receivables Growing